Weekly paclitaxel at the dose schedule used in the current study was well tolerated and demonstrated clinical benefit.

clinicaltrials.gov Identifier: NCT02406781.

No abstract

No abstract

No abstract

No abstract

Conventional chemotherapy have very limited efficacy in patients with advanced chondrosarcoma, the highest benefit being observed in mesenchymal and dedifferentiated chondrosarcoma. These data should be used as a reference for response and outcome in the assessment of investigational drugs in advanced chondrosarcoma.

No abstract